deltatrials
Terminated PHASE3 INTERVENTIONAL 1-arm NCT04200352

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Cerebral Palsy, Dyskinetic
Interventions TEV-50717
Updated 29 times since 2020 Last updated: Apr 10, 2024 Started: Feb 4, 2020 Primary completion: Feb 14, 2023 Completion: Feb 14, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint

Other terminated trials from Teva Branded Pharmaceutical Products R&D, Inc.

More terminations from Teva Branded Pharmaceutical Products R&D, Inc.

A PHASE3 clinical study on Cerebral Palsy, Dyskinetic, this trial is terminated or withdrawn. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 29 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Feb 2024 · 10 months · monthly snapshot~Feb 2024 – ~May 2024 · 3 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

29 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. May 2024 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Feb 2024 — May 2024 [monthly]

    Terminated PHASE3

▶ Show 24 earlier versions

  1. Apr 2023 — Feb 2024 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  2. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  7. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  8. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  9. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE3

  10. Dec 2021 — Mar 2022 [monthly]

    Recruiting PHASE3

  11. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  12. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  13. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  14. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  15. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  16. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  17. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  18. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  19. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  20. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  21. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  22. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  23. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  24. Jan 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Teva Branded Pharmaceutical Products R&D, Inc.
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Blegdamsvej 9, Denmark , Charleston, United States , Dnipro, Dnipropetrovsk Province, Ukraine , Edinburgh, Edinburgh, United Kingdom , Gdansk, Poland , Gdansk, Pomerania Province, Poland , Kazan', Russia , Khabarovsk, Khabarovsk Krai Region, Russia , Krakow, Poland and 20 more locations